Compare First Trust NASDAQ Smart Grid ETF (GRID) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ Smart Grid ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? First Trust NASDAQ Smart Grid ETF trades at $169.87 (market cap $12.08B), while Spyre Therapeutics Inc. Common Stock trades at $78.73 (market cap $7.35B). The key difference: First Trust NASDAQ Smart Grid ETF is the larger of the two by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, First Trust NASDAQ Smart Grid ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Trust NASDAQ Smart Grid ETF for 14 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| GRID | SYRE | |
|---|---|---|
Market Cap | $12.08B | $7.35B |
Volume | 430,482 | 1,624,631 |
Sector | Sector/Thematic | Health |
52-Week High | $199.80 | $108.92 |
52-Week Low | $146.51 | $22.18 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | — | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRID trades at $179.25, up 0.31% on the day, with a bearish technical signal from moving averages and neutral oscillators. The stock is positioned in the smart grid infrastructure sector, benefiting from AI-driven power buildout investments. Recent news highlights its exposure to infrastructure modernization and AI energy demand, though key financial ratios are not disclosed in the provided data.
Outlook is mixed: technicals suggest caution, but thematic tailwinds from AI infrastructure spending offer growth potential. Risks include sector competition and execution challenges. Investors should weigh near-term technical weakness against long-term infrastructure investment trends.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About First Trust NASDAQ Smart Grid ETF
First Trust NASDAQ Smart Grid Infrastructure ETF seeks to track companies involved in smart grid and electricity infrastructure. Its holdings include businesses related to power networks, energy management, and grid technologies.
Read more on GRID →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
